Leerink Remains Cautious on Ionis Pharmaceuticals (IONS) Following Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
May 27, 2016 6:23 AM EDTBMO Capital downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Market Perform with a price target of $26.00 (from $55.00).
Analyst Do Kim commented, "We are downgrading IONS shares to Market Perform from Outperform, following partner GSKs decision to delay the CARDIO-TTR Phase III... More
Needham & Company Cut PT, But Keeps 'Buy' on Ionis Pharmaceuticals (IONS) Amid Update
May 26, 2016 1:35 PM EDTNeedham & Company analyst Chad Messer is sticking with his Buy rating but reducing his target to $55 (from $88) on Ionis Pharmaceuticals (NASDAQ: IONS) after Ionis announced that partner GSK is delaying its decision to initiate that study until after NEURO-TTR reads out in 1H:17. Severe thrombocytopenia... More
Cowen Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
May 26, 2016 11:49 AM EDTCowen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.
Shares of Ionis Pharmaceuticals closed at $35.26 yesterday.
... MoreAlnylam Pharma (ALNY) Gains on Ionis (IONS) Setback
May 26, 2016 11:33 AM EDTAlnylam Pharma (NASDAQ: ALNY) is gaining sharply Thursday (11.9%), related to a setback for Ionis Pharmaceuticals's (Nasdaq: IONS) IONIS-TTRRx program. Ionis' partner GSK has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. IONS is down 32%.
... MoreIonis Pharma (IONS): CARDIO-TTR Trial Uncertainty as GSK Stops Initiation - BMO
May 26, 2016 9:37 AM EDTBMO Capital Markets analyst, Do Kim, notes that Ionis Pharmaceuticals (NASDAQ: IONS) partner GSK will not initiate the CARDIO-TTR Phase III trial, following the FDA clinical hold related to patient safety monitoring in the study design. He believes that the study is probably... More
Ionis Pharma (IONS) Says Glaxo Will Not Initiate CARDIO-TTR Phase 3
May 26, 2016 7:35 AM EDTIonis Pharmaceuticals, Inc. (Nasdaq: IONS) provided an update on the IONIS-TTRRx program. Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardiomyopathy.
GSK, which has an option to exclusively license IONIS-TTRRx, has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. As announced in April 2016, the U.S. Food and Drug... More
